Sab Biotherapeutics, Inc. SABS
We take great care to ensure that the data presented and summarized in this overview for SAB Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SABS
Top Purchases
Top Sells
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Insider Transactions at SABS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 07
2023
|
Eddie Joe Sullivan PRESIDENT |
BUY
Open market or private purchase
|
Direct |
1,740
+0.03%
|
$0
$0.88 P/Share
|
|
Nov 30
2023
|
Michael King CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$0
$0.9 P/Share
|
|
Nov 29
2023
|
Samuel J Reich CEO & EXECUTIVE CHAIRMAN |
BUY
Open market or private purchase
|
Direct |
11,000
+4.78%
|
$0
$0.89 P/Share
|
|
Nov 24
2023
|
Helen K. Ellias |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,857,142
+50.0%
|
-
|
|
Nov 24
2023
|
Andrew Moin |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,584,571
+50.0%
|
-
|
|
Nov 24
2023
|
Sessa Capital (Master), L.P. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,584,571
+50.0%
|
-
|
|
Mar 14
2023
|
Alexandra Kropotova CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
275,000
+50.0%
|
-
|
|
Dec 07
2022
|
Jeffrey G Spragens |
BUY
Grant, award, or other acquisition
|
Direct |
82,987
+17.36%
|
$82,987
$1.21 P/Share
|
|
Dec 07
2022
|
David Charles Link |
BUY
Grant, award, or other acquisition
|
Direct |
41,493
+41.99%
|
$41,493
$1.21 P/Share
|
|
Dec 07
2022
|
Christine E Hamilton |
BUY
Grant, award, or other acquisition
|
Indirect |
82,987
+2.6%
|
$82,987
$1.21 P/Share
|
|
Sep 13
2022
|
Christine E Hamilton |
BUY
Open market or private purchase
|
Direct |
10,000
+0.2%
|
$0
$0.73 P/Share
|
|
Sep 07
2022
|
Eddie Joe Sullivan PRESIDENT |
BUY
Open market or private purchase
|
Direct |
14,000
+0.27%
|
$0
$0.74 P/Share
|
|
Jun 06
2022
|
Alexandra Kropotova CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
May 20
2022
|
Samuel J Reich CEO & EXECUTIVE CHAIRMAN |
BUY
Other acquisition or disposition
|
Direct |
207,001
+49.88%
|
-
|
|
May 20
2022
|
Samuel J Reich CEO & EXECUTIVE CHAIRMAN |
SELL
Other acquisition or disposition
|
Indirect |
2,500,127
-82.03%
|
-
|
|
May 20
2022
|
Jeffrey G Spragens |
BUY
Other acquisition or disposition
|
Direct |
299,002
+48.94%
|
-
|
|
Oct 26
2021
|
Russell P Beyer Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
278
-100.0%
|
$1,946
$7.9 P/Share
|
|
Oct 25
2021
|
Russell P Beyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
129
+31.7%
|
$903
$7.78 P/Share
|
|
Oct 22
2021
|
David Charles Link |
BUY
Grant, award, or other acquisition
|
Indirect |
12,097
+50.0%
|
-
|
|
Oct 22
2021
|
David Charles Link |
BUY
Grant, award, or other acquisition
|
Direct |
15,820
+50.0%
|
-
|